Abstract:The results of the present study showed that intracerebroventricular injection of 5-HT1 and 5-HT2 agonist 1-(3-chlorophenyl) piprazine and Q-CH3-5-HT in rat exagerated the morphine withdrawal syndromes, but there is no effect of 5-HT3 agonist (2-CH3-5-HT) on morphine withdrawal syndromes. It was also found that intracerebroventricular injection of methiothepin mesylate and retanserine, the blockers of 5-HT1 and 5-HT2 receptors, could relieve the morphine withdrawal syndrome dose-dependently. The suppressive effect of retanserine was much stronger than that of metheothepin. This finding may have implication in selecting new therapeutic medicine for morphine withdrawatl syndnomes.